Become a founding member of MedFeeSchedule and become one of the first users of our new commercial payer feature.
Unlock Commercial Payer Rates - Aetna | BCBS | UnitedHealthcare | Cigna
Current CMS pricing and breakdown for Iadna gu pthgn 20bct&fng org.
National Medicare Payment
$634.84
This fee schedule does not publish separate facility and non-facility rates for this code.
Effective Q4 2026
This item has a standard price nationwide. Your local rate will likely match the amount shown above.
| Quarter | National Medicare Payment | YoY % Change |
|---|---|---|
| 2026 Q4 | $634.84 | +0.00% |
| 2026 Q3 | $634.84 | +0.00% |
| 2026 Q2 | $634.84 | +0.00% |
| 2026 Q1 | $634.84 | +0.00% |
| 2025 Q4 | $634.84 | — |
| 2025 Q3 | $634.84 | — |
| 2025 Q2 | $634.84 | — |
| 2025 Q1 | $634.84 | — |
Infectious agent detection by nucleic acid (dna or rna), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique
CPT code 0321U (Infectious agent detection by nucleic acid (dna or rna), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique) had a 2026 Medicare non-facility reimbursement rate of $634.84. This reflects a 0.00% change from the prior year.
The 2026 National Medicare reimbursement for 0321U is $634.84. This item is paid at a standard national rate, so local variation is typically minimal.
Description: Infectious agent detection by nucleic acid (dna or rna), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 a.... Payment policies and coverage rules can still vary by setting and claim details, so confirm final guidance through CMS when needed.
| Component | Office (Non-Fac) | Facility (Hosp) |
|---|---|---|
| Work RVU | ||
| Practice Expense (PE) | ||
| Malpractice (MP) | ||
| Total RVUs | 0.00 | 0.00 |
Compare a payment against the Medicare benchmark for this code.
Medicare rates are used as a benchmark only. Actual payer contracts, modifiers, place of service, units, and billing rules may affect reimbursement. This tool is for educational and operational review purposes, not legal or billing advice.
Facility vs. non-facility pricing most commonly applies to physician services paid under the RVU-based Physician Fee Schedule. For 0321U (Clinical Laboratory Test), the payment methodology may not include both facility and non-facility rates.
Medicare reimbursement is determined by RVUs, geographic adjustments, and the annual conversion factor.
The 2026 National Average Medicare reimbursement rate for 0321U (Clinical Laboratory Test) is $634.84. This rate is effective as of January 1, 2026.
Infectious agent detection by nucleic acid (dna or rna), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique
Facility vs. non-facility differences usually apply to RVU-based physician services. 0321U may not use both facility and non-facility pricing depending on its payment methodology.
Use MedFeeSchedule's Medicare Physician Fee Schedule Lookup Tool on the homepage to estimate your locality-adjusted reimbursement. Medicare payment can vary based on geographic adjustments (GPCI), place of service, and claim specifics.
Coverage depends on medical necessity, setting, and Medicare policy. Some codes may be bundled, contractor-priced, or restricted. Verify final coverage guidance through CMS or your local MAC when applicable.